These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27510982)

  • 1. Impact of quercetin‑induced changes in drug‑metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats.
    Liu Y; Luo X; Yang C; Yang T; Zhou J; Shi S
    Mol Med Rep; 2016 Oct; 14(4):3073-85. PubMed ID: 27510982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quercetin‑3‑O‑β‑D‑glucoside decreases the bioavailability of cyclosporin A through regulation of drug metabolizing enzymes, transporters and nuclear receptors in rats.
    Yang T; Liu Y; Huang X; Zhang R; Yang C; Zhou J; Zhang Y; Wan J; Shi S
    Mol Med Rep; 2018 Sep; 18(3):2599-2612. PubMed ID: 30015887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related changes in mRNA levels of hepatic transporters, cytochrome P450 and UDP-glucuronosyltransferase in female rats.
    Kawase A; Ito A; Yamada A; Iwaki M
    Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):239-44. PubMed ID: 24899460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dextran sulfate sodium-induced colitis and ginseng intervention altered oral pharmacokinetics of cyclosporine A in rats.
    Yang Y; Hu N; Gao XJ; Li T; Yan ZX; Wang PP; Wei B; Li S; Zhang ZJ; Li SL; Yan R
    J Ethnopharmacol; 2021 Jan; 265():113251. PubMed ID: 32810615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemia-reperfusion through distinct mechanisms between CYP3A and P-glycoprotein in the small intestine.
    Ikemura K; Inoue K; Mizutani H; Oka H; Iwamoto T; Okuda M
    Eur J Pharmacol; 2012 Sep; 690(1-3):192-201. PubMed ID: 22749977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Long-Lasting Oatp Inhibition by Typical Inhibitor Cyclosporine A and In Vitro-In Vivo Discrepancy in Its Drug Interaction Potential in Rats.
    Taguchi T; Masuo Y; Kogi T; Nakamichi N; Kato Y
    J Pharm Sci; 2016 Jul; 105(7):2231-9. PubMed ID: 27290622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baicalin reduces ciclosporin bioavailability by inducing intestinal p-glycoprotein in rats.
    Tian X; Chang Y; Wei J; Liu R; Wang L; Zhang J; Zhang X
    J Pharm Pharmacol; 2019 May; 71(5):788-796. PubMed ID: 30663770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-associated differences in transporter gene expression in kidneys of male rats.
    Xu YJ; Wang Y; Lu YF; Xu SF; Wu Q; Liu J
    Mol Med Rep; 2017 Jan; 15(1):474-482. PubMed ID: 27909713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
    Wang Q; Zheng M; Leil T
    CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
    Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
    Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.
    Kageyama M; Namiki H; Fukushima H; Ito Y; Shibata N; Takada K
    Biol Pharm Bull; 2005 Feb; 28(2):316-22. PubMed ID: 15684491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of piperine and quercetin alone or in combination with marbofloxacin on CYP3A37 and MDR1 mRNA expression levels in broiler chickens.
    Patel HB; Patel UD; Mathapati BS; Modi CM
    Res Vet Sci; 2019 Oct; 126():178-183. PubMed ID: 31539794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine.
    Spence R; Mandagere A; Richards DB; Magee MH; Dufton C; Boinpally R
    Clin Pharmacol Ther; 2010 Oct; 88(4):513-20. PubMed ID: 20811346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
    Ieiri I; Higuchi S; Sugiyama Y
    Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ontogeny of Small Intestinal Drug Transporters and Metabolizing Enzymes Based on Targeted Quantitative Proteomics.
    Kiss M; Mbasu R; Nicolaï J; Barnouin K; Kotian A; Mooij MG; Kist N; Wijnen RMH; Ungell AL; Cutler P; Russel FGM; de Wildt SN
    Drug Metab Dispos; 2021 Dec; 49(12):1038-1046. PubMed ID: 34548392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver.
    Hagenbuch N; Reichel C; Stieger B; Cattori V; Fattinger KE; Landmann L; Meier PJ; Kullak-Ublick GA
    J Hepatol; 2001 Jun; 34(6):881-7. PubMed ID: 11451172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smilax glabra Rhizoma affects the pharmacokinetics and tissue distribution of methotrexate by increasing the P‑glycoprotein mRNA expression in rats after oral administration.
    Li Y; Deng S; Ζhao Y; Liu L; Zhao R
    Mol Med Rep; 2017 Nov; 16(5):7633-7640. PubMed ID: 28944899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic interaction between cyclosporine and sirolimus.
    Bai S; Stepkowski SM; Kahan BD; Brunner LJ
    Transplantation; 2004 May; 77(10):1507-12. PubMed ID: 15239612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.